United States-based Parnell Pharmaceuticals has announced that it has developed Nomovid, claimed to be the first antiviral nasal spray in the United States, it was reported on Wednesday.

The company says that the product is easy-to-use, low-cost and can be offered over-the-counter for consumers.

The product is based on a substance licensed by the company from New Mexico Tech University to treat drug-resistant bacteria and fungi such as MRSA and Candida auris. Parnell had been taking the necessary steps to enter the FDA approval process for the MRSA indication, until it reportedly saw very positive results against COVID-19. The company is now filing for the COVID-19 indication instead.